Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Chen

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Science (New York, N.Y.)|January 9, 2025
Bile acid synthesis impedes tumor-specific T cell responses during liver cancerSiva Karthik Varanasi, Dan Chen, Yingluo Liu, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
The Journal of Clinical Investigation|September 9, 2025
Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesisThomas Mandel Clausen, Ryan J Weiss, Jacob R Tremblay, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Science (New York, N.Y.)|January 9, 2025
Bile acid synthesis impedes tumor-specific T cell responses during liver cancerSiva Karthik Varanasi, Dan Chen, Yingluo Liu, et al.
Haematologica|April 23, 2026
Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study resultsMichael J Hochman, Amy S Ruppert, Ying Huang, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
The Journal of Clinical Investigation|September 9, 2025
Antithrombin-binding heparan sulfate is ubiquitously expressed in epithelial cells and suppresses pancreatic tumorigenesisThomas Mandel Clausen, Ryan J Weiss, Jacob R Tremblay, et al.
Nature Medicine|October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, Ross L Levine, Amy S Ruppert, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|October 31, 2022
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlatesAntoine N Saliba, Scott H Kaufmann, Eytan M Stein, et al.
Blood Cancer Journal|April 3, 2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trialFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Pageof 9